TrialPloS one2014

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.

David A Wohl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.